{
      "Rank": 188,
      "Acronym": [
            "ARDS-MSC-205"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg."
      ],
      "ArmGroupInterventionName": [
            "Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
      ],
      "ArmGroupLabel": [
            "Mesenchymal Stromal Stem Cell Treatment"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04447833"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205."
      ],
      "BriefTitle": [
            "Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Uppsala University Hospital"
      ],
      "CompletionDate": [
            "June 30, 2025"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "ARDS, Human",
            "COVID"
      ],
      "ConditionAncestorId": [
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC08",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M14117",
            "M14116",
            "M27297",
            "M27296",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Lung Injury",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000012128",
            "D000012127",
            "D000055371"
      ],
      "ConditionMeshTerm": [
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [
            "This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS)."
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nWilling and able to provide written informed consent prior to performing study procedures (and have given written consent)\nCoronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test at screening\nMale or female patient aged 18 to 65 years old\nPatient must fulfil the Berlin Definition of severe ARDS within 3 weeks to 48 hours prior to enrolment (Will be assessed once the patient has been admitted to the ICU)\nPatient is on respirator support within 3 weeks to 48 hours prior to enrolment (Will be assessed once the patient has been admitted to the ICU)\nPregnancy test in blood confirming negative results before enrolment (for women \u226455 years old)\n\nExclusion Criteria:\n\nHistory of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study\nPatients with history of treated blood and/or solid organ malignancy with recurrence within five years prior to dosing of the ATIMP are to be excluded. Patients with history of cervix cancer and non-melanoma skin cancer with recurrence within two years prior to dosing of the ATIMP are to be excluded\nPregnant or breast feeding female\nPatient with a history of anti-coagulation therapy for other indications that short-term prophylaxis after surgery\nPatients with a history and/ or on-going treatment for entity associated with bleeding disorder or potential risk for bleeding (e.g. inflammatory bowel disease, gastro-esophagitis with or without ulcers, haemophilia and other bleeding disorders, inflammatory musculo-skeletal disease with potential bleeding complications)\nPatients with a history during the latest five years and/or on-going treatment for systemic infection (e.g. Septicaemia due to in vivo foreign body (e.g. stents, catheters, heart valve), tuberculosis, malaria, other opportunistic and parasite infections)\nPrisoner\nAny other irreversible disease or condition for which six-month mortality is estimated to be greater than 50%\nModerate to severe liver failure (Child-Pugh Score >12)\nReduced renal function with a creatinine clearance (Cockcroft-Gault Equation) < 45 mL/min/1.73m2\nSevere chronic respiratory disease with a PaCO2 >50 mmHg or the use of home oxygen\nMajor trauma in the prior 5 days\nLung transplant patient\nPatients on ECMO-support\nPatients with a previous history of severe burns\nDocumented deep venous thrombosis or pulmonary embolism within past three months\nKnown hypersensitivity to DMSO\nInvestigator considers the patient unlikely to comply with study procedures, restrictions and requirements"
      ],
      "EnrollmentCount": [
            "7"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mesenchymal Stromal Stem Cell Treatment"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs)."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
      ],
      "InterventionOtherName": [
            "Allogeneic Bone Marrow Derived Mesenchymal Stem Cells"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Mesenchymal Stromal Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "March 4, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 3, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Uppsala University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Uppsala"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Sweden"
      ],
      "LocationFacility": [
            "Uppsala University Hospital"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "75185"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Uppsala University"
      ],
      "OrgStudyId": [
            "2020-02238"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Uppsala University"
      ],
      "OverallOfficialName": [
            "Oscar Simonsson, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "January 30, 2021"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "The incidence of pre-specified treatment related adverse events of interest (TRAEIs) occurring during the 10 days interval beginning with the start of the ATIMP infusion:\n\nNew ventricular tachycardia, ventricular fibrillation or asystole within 10 days after infusion\nNew cardiac arrhythmia requiring cardioversion within 10 days after infusion\nClinical scenario consistent with transfusion incompatibility or transfusion-related infection within 10 days after infusion\nThromboembolic events (e.g. Pulmonary embolism) within 10 days after infusion\nCardiac arrest or death within 10 days after infusion"
      ],
      "PrimaryOutcomeMeasure": [
            "The incidence of pre-specified treatment related adverse events of interest (TRAEIs)."
      ],
      "PrimaryOutcomeTimeFrame": [
            "From drug administration to day 10 post-infusion"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "All-cause mortality at 60 days and then annually",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the leucocyte Count (number/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the trombocyte Count (number/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of CRP (mg/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of PK (INR)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of creatinine (\u03bcmol/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ASAT (\u03bckat/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ALAT (\u03bckat/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of NT-proBNP (ng/L)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in blood pressure (mmHg)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in body temperature (\u00b0C)",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in pulmonary compliance (dynamic and static) until day 10 post-infusion",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in driving pressure (Plateau pressure- PEEP) until day 10 post-infusion",
            "Changes from baseline (Day 1; prior to administration of ATIMP) in oxygenation (PaO2/FiO2) until day 10 post-infusion",
            "Number of days with ventilator support",
            "Changes in amount of pulmonary bilateral infiltrates assessed by pulmonary X-ray from baseline (Day 1; prior to administration of ATIMP) until day 60",
            "Changes in Sequential Organ Failure Assessment (SOFA) score from baseline (Day 1; prior to administration of ATIMP) and during the ICU-period",
            "Duration of ICU stay and hospital stay (number of days; whole hospital period + calculated from Day 1)",
            "Recovery of lung function assessed by Spirometry (FEV1, Vital Capacity) at day 60 and then annually",
            "To assess development of lung fibrosis using the HRCT Fibrosis Score using Computed tomography (CT) at baseline and on day 1, 3, 7, 10, end of ICU-residence, end of hospital stay, day 60, 6 month and 12 month and end of study (if possible during the infectious stage depending on hospital safety regimen during the pandemic).",
            "Assessment of the patient's physical capacity by 6-Minute-Walk-Test (6MWT), starting at 6 months post Day 1 and then annually",
            "Changes in Quality of Life by assessing the Short Form Health Survey (SF-36) score (starting at 6 months post Day 1 and then annually; patient reported outcome)",
            "Change in blood biomarkers related to the proposed mechanisms of action of KI-MSC-PL-205 in ARDS",
            "Sensitisation tests (test for donor-specific antibodies) against KI-MSC-PL-205 donor"
      ],
      "SecondaryOutcomeMeasure": [
            "Safety; All-cause mortality",
            "Changes in Leucocytes",
            "Changes in Trombocytes",
            "Changes in plasma concentration of C-reactive protein (CRP)",
            "Changes in plasma concentration of Prothrombin complex (PK)",
            "Changes in plasma concentration of Creatinine",
            "Changes in plasma concentration of Aspartate amino transferase (ASAT)",
            "Changes in plasma concentration of Alanine amino transferase (ALAT)",
            "Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)",
            "Changes in Blood pressure",
            "Changes in Body temperature",
            "Efficacy; Changes in pulmonary compliance",
            "Efficacy; Changes in driving pressure (Plateau pressure- PEEP)",
            "Efficacy; Changes in oxygenation (PaO2/FiO2)",
            "Efficacy; Duration of ventilator support",
            "Efficacy; Pulmonary bilateral infiltrates",
            "Efficacy; Sequential Organ Failure Assessment (SOFA) score",
            "Efficacy; Hospital stay",
            "Lung function",
            "Lung fibrosis",
            "Six minutes walk test",
            "Changes in Quality of life",
            "Blood biomarkers",
            "Sensitisation test"
      ],
      "SecondaryOutcomeTimeFrame": [
            "60 days post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
            "Baseline (pre-infusion),day 1, 2, 3, 4, 7, 10 and 60 post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, end of ICU",
            "Day 60 post-infusion",
            "Day 60 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 3, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
            "Baseline (pre-infusion), day 60 post-infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 17, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "March 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 25, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 20, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "June 24, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}